REC-3964 / Recursion Pharma - LARVOL DELTA

ALDER: The Clostridioides Difficile Trial of REC-3964 (clinicaltrials.gov) - P2 | N=80 | Active, not recruiting | Sponsor: Recursion Pharmaceuticals Inc. | Recruiting ➔ Active, not recruiting

Enrollment closed • Infectious Disease

Recursion Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire) - "As part of this prioritization, the Company will discontinue development and/or pursue partnering opportunities for the following clinical programs: REC-3964 (C. difficile): The Company will consider out-licensing opportunities....Evolved treatment options result in low recurrence rates (~5%); thus limiting unmet need. Strategic decision to focus on other areas with greater unmet need."

Discontinued • Infectious Disease

ALDER: The Clostridioides Difficile Trial of REC-3964 (clinicaltrials.gov) - P2 | N=80 | Recruiting | Sponsor: Recursion Pharmaceuticals Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease

ALDER: The Clostridioides Difficile Trial of REC-3964 (clinicaltrials.gov) - P2 | N=80 | Not yet recruiting | Sponsor: Recursion Pharmaceuticals Inc.

New P2 trial • Infectious Disease